STS肺癌肺切除术复合评分评级
结果显示总体手术死亡率1.3%,主要并发症率7.9%,且是否将微创入路纳入风险调整仅改变3%中心的星级。
要点
- STS肺癌肺切除术复合评分基于风险调整死亡率和并发症率两个结局。
- 214个中心获星级评定:7个1星、194个2星、13个3星。
- 微创入路纳入风险调整后仅3%(6/214)中心评级改变。
核心结论
- STS GTSD参与中心肺癌切除术的死亡率和并发症率较低。
- 淋巴结数据提示参与中心符合当代分期标准。
- 微创入路应用在不同中心间差异较大。
- 对手术入路进行风险调整后仅3%参与中心的评级发生变化。
研究设计与样本
- 研究人群包括256个中心的38,461例肺癌切除术患者。
- 对年病例数≥30的214个中心,使用95%贝叶斯可信区间创建星级评级。
主要发现
- 总体手术死亡率为1.3%(495/38,461)。
- 主要并发症率为7.9%(3,045/38,461)。
- 检查淋巴结中位数为10枚(四分位距5至16)。
- 采样淋巴结站中位数为4站(四分位距3至5)。
- 阳性切缘率为3.7%(1,420/38,461)。
关键数值与推荐
- 星级评定基于风险调整死亡率和并发症率的复合评分。
- 214个中心中,7个为1星、194个为2星、13个为3星。
- 70.6%的切除术通过微创入路完成。
- 将微创入路纳入风险调整后,3%(6/214)中心的星级评级改变。
临床怎么用
- 该复合评分可用于评估肺癌肺切除术的质量。
- 参与中心应关注淋巴结采样达标情况。
- 微创入路应用存在中心间差异,需关注其影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Society of Thoracic Surgeons (STS) General Thoracic Surgery Database (GTSD) has developed composite quality measures for lobectomy and esophagectomy. This study sought to develop a composite measure including all resections for lung cancer. METHODS: The STS lung cancer composite score is based on 2 outcomes: risk-adjusted mortality and morbidity. GTSD data were included from January 2015 to December 2017. "Star ratings" were created for centers with 30 or more cases by using 95% Bayesian credible intervals. The Bayesian model was performed with and without inclusion of the minimally invasive approach to assess the impact of approach on the composite measure. RESULTS: The study population included 38,461 patients from 256 centers. Overall operative mortality was 1.3% (495 of 38,461). The major complication rate was 7.9% (3045 of 38,461). The median number of nodes examined was 10 (interquartile range, 5 to 16); the median number of nodal stations sampled was 4 (interquartile range, 3 to 5). Positive resection margins were identified in 3.7% (1420 of 38,461). A total of 214 centers with 30 or more cases were assigned star ratings. There were 7 1-star, 194 2-star, and 13 3-star programs; 70.6% of resections were performed through a minimally invasive approach. Inclusion of minimally invasive approach, which was adjusted for in previous models, altered the star ratings for 3% (6 of 214) of the programs. CONCLUSIONS: Participants in the STS GTSD perform lung cancer resection with low morbidity and mortality. Lymph node data suggest that participants are meeting contemporary staging standards. There is wide variability among participants in application of minimally invasive approaches. The study found that risk adjustment for approach altered ratings in 3% of participants.
引用
- Broderick SR, Grau-Sepulveda M, Kosinski AS, et al. The Society of Thoracic Surgeons Composite Score Rating for Pulmonary Resection for Lung Cancer. Ann Thorac Surg. 2019. PMID: 31689407. doi:10.1016/j.athoracsur.2019.08.114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。